Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin

NCT ID: NCT01107431

Last Updated: 2011-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study concluded that consumption of the LA-Cr supplement in conjunction with a 70-gram sucrose challenge led to a significant reduction of capillary blood glucose and venous insulin as compared to the sucrose challenge without the LA-Cr supplement. This finding may provide an important tool to reduce the adverse effects associated with elevated glucose and insulin levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sucrose with Dietary Supplement

Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium

Group Type ACTIVE_COMPARATOR

L-Arabinose and Chromium

Intervention Type DIETARY_SUPPLEMENT

Consumed 70 grams of sucrose simultaneously taking a dietary supplement

Sucrose without Dietary Supplement

Consumed 70 grams of sucrose without simultaneously taking the dietary supplement

Group Type ACTIVE_COMPARATOR

Sucrose without dietary Supplement

Intervention Type DIETARY_SUPPLEMENT

Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-Arabinose and Chromium

Consumed 70 grams of sucrose simultaneously taking a dietary supplement

Intervention Type DIETARY_SUPPLEMENT

Sucrose without dietary Supplement

Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

70 grams of cane sugar along with supplement 70 grams of cane sugar with supplement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All study subjects were required to contact their family physician to ensure they had no medical conditions that would preclude their participation.

Exclusion Criteria

* Diabetics, and
* Those not approved by their physicians.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Integrative Health Technologies, Inc.

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Integrative Health Technologies, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gilbert R Kaats, PhD

Role: PRINCIPAL_INVESTIGATOR

Integrative Health Technologies

Harry G Preuss, MD

Role: PRINCIPAL_INVESTIGATOR

Georgetown University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Integrative Health Technologies

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kaats GR, Keith SC, Keith PL, Leckie RB, Perricone NV, Preuss HG. A combination of l-arabinose and chromium lowers circulating glucose and insulin levels after an acute oral sucrose challenge. Nutr J. 2011 May 6;10:42. doi: 10.1186/1475-2891-10-42.

Reference Type DERIVED
PMID: 21548959 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pharmachem 40-47

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chromium and Insulin Resistance
NCT00846248 COMPLETED NA
Chromium and Insulin Action
NCT00283777 COMPLETED PHASE4